Form 4 Filing for IMMUNIC, INC. - Officer Transaction

This filing details a Form 4 submission by Jason Tardio, President and COO of IMMUNIC, INC. (IMUX). On June 29, 2026, Tardio was granted 253,000 stock options for the company's Common Stock. These options were conditionally approved by the Board of Directors, pending stockholder approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders. The options have an exercise price of $11.60 and an expiration date of April 2, 2036. Vesting commences on April 2, 2027, with 25% vesting on that date, followed by equal monthly increments over the subsequent 36 months. The filing also notes that the options were granted under a plan that received stockholder approval.